Disclosed are compounds of formula I and II that are bradykinin B
1
receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B
1
receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.
本发明公开了式I和式II的化合物,它们是
缓激肽B1受体拮抗剂,可用于治疗哺乳动物中由
缓激肽B1受体介导的疾病,或缓解与疾病条件相关的不良症状。其中某些化合物表现出增强的效力,预计也会表现出增强的持续时间。